November 8, 2010: Allan B. Haberman, Ph.D. was quoted in an article entitled “Bristol-Myers Squibb reaps biologics in ZymoGenetics windfall”, in the November 2010 issue of Nature Biotechnology. The article focused on the acquisition of ZymoGenetics (Seattle, WA) by Bristol-Myers Squibb (BMS), with a special focus on ZymoGenetics’ hepatitis C drug pegylated interferon-lambda.

Read full article here.  (subscription required)

November 4, 2010: Cambridge Healthtech Institute (CHI) announced the publication of a new book-length report, RNAi Therapeutics: Second Generation Candidates Build Momentum, by Allan B. Haberman, Ph.D. This new Insight Pharma Report examines the science behind therapeutic RNAi (RNA interference) and miRNA (microRNA), technologies for design of therapeutic oligonucleotides that work via an RNAi or miRNA-modulating mechanism, technologies for design of delivery vehicles, and leading specialty companies in the therapeutic RNAi/miRNA industry sector.

The report also includes a discussion of the outlook for the therapeutic RNAi/miRNA industry sector, including strategic issues such as technological prematurity and the development of enabling technologies, the role of Big Pharma investment, and the impact of patent litigation and cross-licensing in shaping the RNAi/miRNA sector. It also includes a scenario for the development of RNAi and miRNA-based drugs. Also included are transcripts of interviews with five leaders of biotech companies in the RNAi/miRNA industry sector.

For more information on the report, or to order it, see the CHI Insight Pharma Reports website.

June 4, 2010: Haberman Associates’ Biopharmconsortium Blog, formerly at http://biopharmconsortium.blogspot.com, has moved to our own site. You can now find it at https://biopharmconsortium.com/blog/.

We started the Biopharmconsortium Blog in July of 2009. The blog contains expert commentary on recent life science industry news and recent published scientific reports and business articles.

We hope that you will continue to visit and subscribe to our blog in its new location. We also welcome comments and discussions of our blog articles from people in the life science community, including companies, academic institutions, and disease organizations and patient advocates.

March 16, 2010: “Reducing Attrition In Silico” by Allan B. Haberman, Ph.D. was published in the March-April 2010 issue of Bio-IT World. This article is based on an excerpt from Chapter 8 of the recently published book-length report Animal Models for Therapeutic Strategies.

March 5, 2010: Cambridge Healthtech Institute (CHI) announced the publication of a new book-length report, Animal Models for Therapeutic Strategies, by Allan B. Haberman, Ph.D. This new Insight Pharma Report discusses the use of animal models to develop new paradigms for drug discovery and development in important human diseases. The report also discusses strategies for developing more predictive models of drug efficacy. Poorly predictive animal models are a major reason for Phase II and Phase III pipeline drug attrition. Thus this new report complements our May 2009 Insight Pharma Report, Approaches to Reducing Phase II Attrition.

For more information on the report, or to order it, see the CHI Insight Pharma Reports website.